President Trump Announces Deal to Lower Weight Loss Drug Prices
President Trump recently announced a groundbreaking deal with two of the world’s largest pharmaceutical manufacturers, Eli Lilly and Novo Nordisk, to drastically lower the price of weight loss drugs for some Americans. The agreement aims to make these life-changing medications more affordable for eligible patients on Medicare, Medicaid, and those using the planned “TrumpRx” pharmaceutical website.
Under the deal, the price per month for most eligible people will be $245 to $350 on average, which is significantly lower than the current cost of up to $1,350 per month. This reduction in price is expected to have a substantial impact on the lives of millions of Americans struggling with obesity. According to the Centers for Disease Control and Prevention (CDC), about 40% of Americans are obese, which is one of the leading causes of preventable deaths in the United States.
Details of the Weight Loss Drug Price Deal
The TrumpRx website, expected to launch by the end of this year, will allow customers to buy prescription drugs directly from pharmaceutical companies without going through insurance. When purchased through TrumpRx, the cost will be around $350 per month for injections of Ozempic and Wegovy. The new pricing will go into effect in January, and officials hope it will kick in for Medicare in mid-2026.
For eligible patients on Medicaid and Medicare, the cost will be $245 for Ozempic, Wegovy, Mounjaro, and Zepbound, with a Medicare copay of $50. However, not everyone will be eligible for the lowest prices. According to senior administration officials, the lower costs will be available for Medicare patients with a BMI over 27 who have also been diagnosed as pre-diabetic or have had a stroke, myocardial infarction, or peripheral artery disease, as well as those with a BMI over 30 who have stage-three kidney disease or other qualifying comorbidities.
Administration officials believe that about 10% of Medicare patients will be eligible for the lower prices, which could save around $170 billion over time from the reduced risks of obesity in the Medicare population. As Health and Human Services Secretary Robert F. Kennedy Jr. noted, “This is not about losing weight — this is about making America healthy again. This is about preventing strokes, this is about preventing end-stage renal disease.”
Expert Insights and Future Plans
While some analysts have raised concerns that the “most-favored-nation” pricing being promised could have a muted impact on Medicaid patients, the administration remains committed to its goal of increasing access to affordable healthcare. As President Trump stated, “I call it the fat pill or the fat drug. Sometimes it works, I guess, for people. The ones I’ve seen, it hasn’t worked so well.” The administration is also working to get healthier foods into schools and the military and to increase physical activity in schools, with new dietary guidelines expected to be released soon.
Aaron Navarro contributed to this report. For more information on the deal and its implications, visit Here
Image Source: www.cbsnews.com
